Second-Line Oxaliplatin and Irinotecan Versus Irinotecan Alone for Gemcitabine and S-1 Refractory Pancreatic Cancer
PHASE2CompletedINTERVENTIONAL
Enrollment
80
Participants
Timeline
Start Date
September 1, 2015
Primary Completion Date
September 30, 2017
Study Completion Date
December 31, 2017
Conditions
Pancreatic Neoplasms
Interventions
DRUG
Irinotecan
DRUG
Oxaliplatin
Trial Locations (1)
310006
First affiliated hospital, Zhejiang University, Hangzhou
All Listed Sponsors
lead
Zhejiang University
OTHER
NCT02558868 - Second-Line Oxaliplatin and Irinotecan Versus Irinotecan Alone for Gemcitabine and S-1 Refractory Pancreatic Cancer | Biotech Hunter | Biotech Hunter